- Home
- COLL vs HSII Comparison
COLL vs HSII Comparison
Compare COLL & HSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- HSII
- Stock Information
- Founded
- COLL 2002
- HSII 1953
- Country
- COLL United States
- HSII United States
- Employees
- COLL N/A
- HSII N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- HSII Diversified Commercial Services
- Sector
- COLL Health Care
- HSII Consumer Discretionary
- Exchange
- COLL Nasdaq
- HSII Nasdaq
- Market Cap
- COLL 1.1B
- HSII 1.0B
- IPO Year
- COLL 2015
- HSII 1999
- Fundamental
- Price
- COLL $35.95
- HSII $58.78
- Analyst Decision
- COLL Strong Buy
- HSII Buy
- Analyst Count
- COLL 4
- HSII 2
- Target Price
- COLL $44.25
- HSII $57.50
- AVG Volume (30 Days)
- COLL 311.7K
- HSII 554.1K
- Earning Date
- COLL 11-06-2025
- HSII 11-03-2025
- Dividend Yield
- COLL N/A
- HSII 1.02%
- EPS Growth
- COLL N/A
- HSII N/A
- EPS
- COLL 1.06
- HSII 1.72
- Revenue
- COLL $707,007,000.00
- HSII $1,213,437,000.00
- Revenue This Year
- COLL $21.29
- HSII $11.42
- Revenue Next Year
- COLL $3.36
- HSII $1.39
- P/E Ratio
- COLL $34.09
- HSII $34.17
- Revenue Growth
- COLL 22.61
- HSII 12.82
- 52 Week Low
- COLL $23.23
- HSII $36.87
- 52 Week High
- COLL $39.95
- HSII $58.79
- Technical
- Relative Strength Index (RSI)
- COLL 59.69
- HSII 77.71
- Support Level
- COLL $33.89
- HSII $58.31
- Resistance Level
- COLL $35.90
- HSII $58.31
- Average True Range (ATR)
- COLL 1.05
- HSII 0.15
- MACD
- COLL 0.27
- HSII -0.27
- Stochastic Oscillator
- COLL 89.72
- HSII 94.53
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.